Pazopanib: A novel multitargeted tyrosine kinase inhibitor

被引：162

作者：

Sonpavde G. ^{[1
]}

Hutson T.E. ^{[1
]}

机构：

[1] Texas Oncology P.A., Baylor Sammons Cancer Center, Dallas, TX 75246

来源：

Current Oncology Reports | 2007年 / 9卷 / 2期

关键词：

Vascular Endothelial Growth Factor; Renal Cell Carcinoma; Sorafenib; Lapatinib; Synovial Sarcoma;

D O I：

10.1007/s11912-007-0007-2

中图分类号：

学科分类号：

摘要：

Pazopanib (GW786034) is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-α, platelet-derived growth factor receptor-β and c-kit. Preclinical evaluation has revealed excellent antiangiogenic and antitumor activity, and synergism was observed in combination with chemotherapeutic drugs. Significant antitumor activity was found in animal models of a variety of tumors, accompanied by desirable pharmacokinetics and oral bioavailability. Phase I clinical trials have revealed manageable toxicities and desirable pharmacokinetics as well as activity in renal cancer and several other tumors. Ongoing trials are further evaluating pazopanib in a variety of malignancies. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：115 / 119

页数：4

共 25 条

[21]

Podar K., Tonon G., Abtahi D., Et al., In vitro and in vivo activity of the VEGF receptor inhibitor PAZOPANIB (GW786034) in Multiple myeloma: Therapeutic implications, Proc Amer Assoc Cancer Res, 47, (2006)

[22]

Suttle A.B., Hurwitz H., Dowlati A., Et al., Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors, J Clin Oncol Proc ASCO, 22, 14 S, (2004)

[23]

Hurwitz H., Dowlati A., Savage S., Et al., Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors, J Clin Oncol, 23, 16 S, (2005)

[24]

Hutson T.E., Bukowski R.M., A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma, Clin Genitourin Cancer, 4, pp. 296-298, (2006)

[25]

Rini B.I., Small E.J., Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma, J Clin Oncol, 23, pp. 1028-1043, (2005)

← 1 2 3 →